Affiliation:
1. Shiraz University of Medical Sciences
Abstract
Abstract
Two series of novel imidazo[1,2-a]pyridine-2-carbohydrazide derivatives have been designed, synthesized and evaluated for cytotoxic activity. Target compounds were designed in two series: aryl hydrazone derivatives that were devoid of triazole moiety (7a-e) and aryl triazole group (11a-e). In vitro cytotoxicity screening was carried out using MTT assay against three human cancer cells including breast cancer (MCF-7), colon cancer (HT-29) and leukemia (K562) cell lines. Compound 7d bearing 4-bromophenyl pendant from aryl hyrazone series exhibited the highest cytotoxic potential with IC50 values of 22.6 µM and 13.4 µM against MCF-7 and HT-29 cells, respectively. Cell cycle analysis revealed that 7d decreased the cells in the G2/M phase at 50 and 100 µM concentrations. Overall, 7d could serve as a suitable candidate for further modifications as a lead anticancer structure.
Publisher
Research Square Platform LLC
Reference24 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung H;CA Cancer J Clin,2021
2. Imidazo [1, 2-a] pyridines: Promising drug candidate for antitumor therapy;Goel R;Curr Top Med Chem.,2016
3. Synthesis, molecular docking and anti-mycobacterial evaluation of new imidazo [1, 2-a] pyridine-2-carboxamide derivatives;Jose G;Eur J Med Chem,2015
4. Design, synthesis, computational and biological evaluation of new anxiolytics;Geronikaki A;Bioorg. Med. Chem,2004
5. An Overview of Various Heterocyclic Imidazopyridine, Triazolopyridine and Quinoline Derivatives and Their Biological Significances;Asif M;Mor J Chem,2017